Cancer stem-like cells (CSC) have been widely studied but their clinical relevance has yet to be established in breast cancer (BC). Here we report the establishment of primary breast tumor-derived xenografts (PDXs) that encompass the main diversity of human BC and retain the major clinicopathological features of primary tumors. 
Introduction
Heterogeneity is a limitation to cure breast cancer (BC), overcome recurrences and metastases (1) . A major cause of heterogeneity is the hierarchical cellular organization: that endows a small, phenotypically distinct population of cancer stem cells (CSC) with the capacity to support tumor growth, metastasis and therapeutic resistance (2, 3, 4, 5, 6, 7, 8, 9, 10, 11) . Multiple pools of stem cells have been identified within a tumor by different means including (12, 13, 14) mouse lineage tracing experiments (15, 16, 17) . To measure the capacity of a subset of tumor cells to transfer a cancer, tumorigenesis assays with iso-or xenogenic transplantation have been used for many years. They evaluate both tumor-initiating and self-renewal capacities and are widely used to assess CSC activity. They have demonstrated that leukemia and many solid tumors are organized along a hierarchical model (18, 19, 20) . Orthotopic BC xenografts have been shown to keep the features of their corresponding human tumors and to predict prognosis in patients (21) . Yet, the validity of xenotransplant assays for CSC studies has been questioned. The use of highly immunodeficient mice increases the frequency of tumorigenic cells in certain types of cancers such as melanoma (22, 23) . Furthermore, this model tests the CSCs, influence clinical outcome. A recent study has shown emerging evidence supports the idea that properties of leukemic stem cells (LSCs) may be associated with prognosis (24) . Here, we report the establishment of a bank of patient-derived xenografts (PDX) from primary breast cancer (xenobank). We found that a xenograft retains the main features of its cognate primary tumor and that successful engraftment is correlated with the presence of CSCs in the primary tumor, and predicts prognosis in patients. We established the gene expression signatures (GES) of functionally validated CSC populations (breast CSC-GES) and tested their clinical relevance in patients with breast cancers. This functionally-validated CSC population is correlated with survival and expresses genes governing stem cell functions, supporting a major prediction of the CSC model and opening further promises for new anti-CSC therapies using valid preclinical models. dissociated, 1x106 cells were implanted orthotopically in humanized cleared fat pads of NSG (NOD/Shi-scid/IL-2Rγnull) mice for establishing xenotransplants as previously described (19) 
(Supporting information).
Flow cytometry analysis. The analysis was processed on single cell suspension from our patient-derived xenografts (PDXs) obtained as described above.
ALDEFLUOR kit (StemCell technologies) was used to isolate the population with high ALDH enzymatic activity as previously described (19) . In order to eliminate cells of mouse origin from the PDXs, we used staining with an anti-H2Kd antibody (BD biosciences, 1/200, 20 min on ice) followed by staining with a secondary antibody labeled with phycoerythrin (PE) (Jackson labs, 1/250, 20 min on ice).
Tumorigenicity assay. We evaluate the outgrowth potential of each population (ALDEFLUOR-positive, ALDEFLUOR-negative, Unselected) sorted from three different PDXs (CRCM226 x, CRCM174 x, CRCM168 x) and injected in cleared humanized fat pads of NSG mice. We performed serial passages in vivo, using limiting dilutions of ALDEFLUOR-positive, -negative and unselected cells (50,000 cells; 5,000 cells; 3,000 cells; 500 cells; 300 cells). For each PDX model and for each limiting dilutions 10 fat pads were injected. Each tumors generated with 500 sorted cells were serially re-implanted three times and in 10 different fat pads. Each mouse that present a tumor reaching a size of 10mm was considered as a tumor-bearing mouse.
optimize the reverse transfection of SUM159 and S68 cells using lipofectamine RNAiMAX (Invitrogen). Five thousand cells were plated in triplicate in 96-well plates with 0.25 pmol of siRNA in 25ul of Opti-MEM I Medium. The ALDEFLUOR-positive population was evaluated in triplicate at 72-h after lipofection. We have validated that
CSCs and nontumorigenic cells were equally transfected (data not shown). We miniaturized the ALDEFLUOR assay for CSC-enriched population detection per cell in 96-wells plate. For each well we used 0.25 ul of substrate (BAAA) and 100 ul of ALDEFLUOR buffer. We used an automated FACS (LSR2) to detect the ALDEFLUOR-positive population in each well. Each experiments were controlled in 6-plicate using cells incubated with 0.5ul of DEAB. The mini siRNA library of 19 genes was designed by Qiagen based on a published library siRNA that have been shown in peer reviewed publication to provide effective gene silencing. We used three siRNAs per selected gene, most likely in triplicates and considered as a "hit" each siRNA construct that induces a variation of the number of ALDEFLUOR-positive cells over a threshold of two-fold the CSC proportion detected in the control (BCLs infected with a MOCK siRNA). Cell viability was evaluated using DAPI staining.
siRNA screen and SFE analysis. We have performed the siRNA screen with both BCLs following the reverse transfection protocol described before. Then, 72-h after lipofection, BCLs were dissociated and plated as single cells in ultra-low attachment plates (Corning, Acton, MA, www.sigmaaldrich.com) at low density (1,000 viable cells per milliliter). Cells were grown as previously described (27) . After 5 days of suspension culture, the capacity of cells to form tumorspheres (SFE) was quantified.
Statistical analysis. Statistical analyses used the SPSS software (version 10.0.5) and are described in Supporting information.
Results

Generation of patient-derived tumor xenografts (PDXs).
We transplanted 74 fresh primary breast tumors from 71 different individuals into cleared and humanized mammary fat pads of female NSG mice. All implanted tumors were from primary tumor and not from metastasis. The 74 primary tumors implanted cover the main histoclinical features met in an unselected set of breast tumors (Table SI) . Twenty
PDXs were established out of the 74 primary samples transplanted with an engraftment rate of 27%. We successfully maintained 13 PDXs through serial passages (transplantable rate: 17.5%); seven were lost between the first and the fourth passage. The average delay of growth of PDXs was 212 days (range 77-466).
PDX growth kinetic (time to reach 10 mm) was stable or accelerated with serial passages ( Figure S1 ).
PDXs maintain the histological and phenotypic features of primary tumors. We compared histology, SBR grade and pathological phenotype (based on ERBB2, ER, PR, Ki67, P53 protein expression) of PDXs with those of the cognate primary tumors.
We observed a striking preservation of the main histological ( Figure 1A-B (Figure S2 ). We observed an almost perfect preservation of the genomic profiles in paired PDXs with a correlation score of 0.81 ( Figure 1D) . Furthermore, late passages in mice (CRCM168 X P11, CRCM226 X P10, CRCM237 X P8) preserved a genomic profile identical to early passages (P0 to P2) ( Figure 1D ). We profiled 19 paired primary tumors/PDXs using Affymetrix whole-genome oligonucleotide microarrays and determined the molecular subtypes by using the PAM50 predictor. 
BCSC-GES is associated with poor prognosis in BC.
We studied the correlation between the BCSC-GES and histoclinical data using 13 clinically annotated gene expression data sets corresponding to 2,609 patients (Table SV) . Based on the BCSC-GES, the samples were classified as "BCSC-like" (1,443 samples) or "non-BCSC-like" (1,196 samples) . Correlations were found between these two classes and all histoclinical features except patient's age and histological type: as compared to "non-BCSC-like" samples, "BCSC-like" samples were more frequently SBR grade 3, with a TNBC (triple negative breast cancer) phenotype and axillary lymph node metastasis ( Table SVI) . The prognostic value regarding metastasis-free survival (MFS) was tested within the 1,642 patients with available follow-up (8 out of 13 datasets). The 5-year MFS was 70% (95%CI, 67-74) in the "BCSC-like" group and 80% (95%CI 77-83) in the "non-BCSC-like" group (p=5.5e-04, log-rank test) ( Figure   3C ). In multivariate analysis, all these variables remained significant, including the BCSC-GES-based classification (p = 0.027; hazard ratio (HR= 1.39; 95%CI [1.04- Figure 3D) , suggesting that our BCSC-GES determined in our PDXs was independently associated with prognosis in primary BC.
1.87]) (
Identification of a "common" stem cell core transcriptional program. To gain insight into the molecular mechanisms that govern stem cell intrinsic functions, we searched for common expression patterns between our 837-gene BCSC-GES and three stemness GES defined from embryonic, neural, and hematopoietic stem cells (29). Enrichment test was significant with each of the tested stemness GES and the core stemness GES (3SC) defined by Ramalho-Santos et al. (Table SVII) . By contrast, no enrichment was found between our BCSC-GES and the 65-gene signature identified to be upregulated in differentiated cells. A total of 19 genes were common to the four stem cell signatures (BCSC, ESC, HSC,NSC) ( Figure 3E ).
These leading genes were called the core-enriched 4SC genes (CE-4SC). We then 
derived a metagene classifier based on the combined expression of these 19 genes and determined its prognostic relevance in our public data set of 1,642 BC patients.
Based on the metagene, two classes of patients were defined and associated with different MFS (Figure S12) implicated in oxidative phosphorylation, detoxification, lipid metabolism, and genomic stability. Some of these genes encode drug resistance enzymes (UMPS) (36) , or cell cycle regulators through P27 function (GFER) (37, 38) . Metabolic alterations in tumor cells are thought to be important for the tumor phenotype and evolution, and to affect response to therapy (39) . In embryonic, neural, normal and tumoral breast tissues, stem/progenitor cells contain lower level of Reactive Oxygen Species (ROS) than their more mature progeny, sustaining their relative resistance to radiation (40, 41) . In leukemia, oxidative phosphorylation triggers genomic instability and is a putative mechanism explaining relapse after tyrosine kinase inhibitor treatment (42, 43) .
Noteworthy, aldehyde dehydrogenase, a hallmark of embryonic, normal adult tissue and cancer stem cells oxidizes aldehydes to the corresponding carboxylic acids (44) . 237x  226x  168x  162x  181x  174x  183x  184x  177x  180x  256x  216x  258x  268x  274x  272x  214x  224x 172x 
